{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:19:15Z","timestamp":1790313555111,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.beha.2009.05.004","type":"journal-article","created":{"date-parts":[[2009,12,2]],"date-time":"2009-12-02T10:19:00Z","timestamp":1259749140000},"page":"367-379","source":"Crossref","is-referenced-by-count":17,"title":["Cause and management of therapy resistance"],"prefix":"10.1016","volume":"22","author":[{"given":"Andreas","family":"Hochhaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Erben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"La Ros\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.beha.2009.05.004_bib1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia-advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.05.004_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(04)91001-9","article-title":"Imatinib as a paradigm of targeted therapies","volume":"91","author":"Druker","year":"2004","journal-title":"Adv Cancer Res"},{"issue":"8","key":"10.1016\/j.beha.2009.05.004_bib3","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Leukemia"},{"issue":"33","key":"10.1016\/j.beha.2009.05.004_bib4","doi-asserted-by":"crossref","first-page":"34227","DOI":"10.1074\/jbc.M402290200","article-title":"A Bcr\/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2","volume":"279","author":"Dai","year":"2004","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.beha.2009.05.004_bib5","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2009.05.004_bib6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2009.05.004_bib7","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2009.05.004_bib8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2009.05.004_bib9","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1038\/sj.leu.2403157","article-title":"Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha\/ara-C","volume":"17","author":"M\u00fcller","year":"2003","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2009.05.004_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.beha.2009.05.004_bib11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.beha.2009.05.004_bib12","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2009.05.004_bib13","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2009.05.004_bib14","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2009.05.004_bib15","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","article-title":"Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up","volume":"103","author":"Lahaye","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.beha.2009.05.004_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1389557043487321","article-title":"Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment","volume":"4","author":"Cowan-Jacob","year":"2004","journal-title":"Mini Rev Med Chem"},{"issue":"12","key":"10.1016\/j.beha.2009.05.004_bib17","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2009.05.004_bib18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate","volume":"18","author":"Illmer","year":"2004","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2009.05.004_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00062752-200207000-00007","article-title":"Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia","volume":"9","author":"Gorre","year":"2002","journal-title":"Curr Opin Hematol"},{"issue":"2 Suppl. 2","key":"10.1016\/j.beha.2009.05.004_bib20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/shem.2003.50045","article-title":"Cytogenetic and molecular mechanisms of resistance to imatinib","volume":"40","author":"Hochhaus","year":"2003","journal-title":"Semin Hematol"},{"issue":"2","key":"10.1016\/j.beha.2009.05.004_bib21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.beha.2009.05.004_bib22","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2009.05.004_bib23","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.leu.2404137","article-title":"The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib","volume":"20","author":"Khorashad","year":"2006","journal-title":"Leukemia"},{"issue":"2 Suppl. 2","key":"10.1016\/j.beha.2009.05.004_bib24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/shem.2003.50046","article-title":"Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment","volume":"40","author":"Roche-Lestienne","year":"2003","journal-title":"Semin Hematol"},{"issue":"6","key":"10.1016\/j.beha.2009.05.004_bib25","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2009.05.004_bib26","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","article-title":"Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment","volume":"105","author":"Chu","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2009.05.004_bib27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2009.05.004_bib28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2005.05606.x","article-title":"Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors","volume":"130","author":"Angstreich","year":"2005","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.beha.2009.05.004_bib29","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"Soverini","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2009.05.004_bib30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2009.05.004_bib31","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development","volume":"19","author":"Burchert","year":"2005","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.beha.2009.05.004_bib32","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.beha.2009.05.004_bib33","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2002-03-0777","article-title":"The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML","volume":"100","author":"O'Dwyer","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2009.05.004_bib34","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/sj.leu.2402813","article-title":"Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate","volume":"17","author":"Schoch","year":"2003","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2009.05.004_bib35","first-page":"1333","article-title":"The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations","volume":"9","author":"Mohamed","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.beha.2009.05.004_bib36","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood-2003-02-0371","article-title":"Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate","volume":"103","author":"O'Dwyer","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2009.05.004_bib37","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/sj.leu.2403399","article-title":"Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia","volume":"18","author":"Terre","year":"2004","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2009.05.004_bib38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cancergencyto.2004.06.011","article-title":"Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression","volume":"157","author":"Bacher","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"issue":"5531","key":"10.1016\/j.beha.2009.05.004_bib39","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.beha.2009.05.004_bib40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.12588","article-title":"Monitoring treatment of chronic myeloid leukemia","volume":"93","author":"Baccarani","year":"2008","journal-title":"Haematologica"},{"issue":"5486","key":"10.1016\/j.beha.2009.05.004_bib41","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.beha.2009.05.004_bib42","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.leu.2403307","article-title":"Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography","volume":"18","author":"Deininger","year":"2004","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.beha.2009.05.004_bib43","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1373\/clinchem.2004.031112","article-title":"Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib","volume":"50","author":"Soverini","year":"2004","journal-title":"Clin Chem"},{"issue":"7","key":"10.1016\/j.beha.2009.05.004_bib44","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1373\/clinchem.2004.034801","article-title":"Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib","volume":"50","author":"Irving","year":"2004","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.beha.2009.05.004_bib45","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.beha.2009.05.004_bib46","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","article-title":"Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"110","author":"Pfeifer","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2009.05.004_bib47","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/sj.leu.2403935","article-title":"A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib","volume":"19","author":"Crossman","year":"2005","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2009.05.004_bib48","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3324\/haematol.12964","article-title":"ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"issue":"29","key":"10.1016\/j.beha.2009.05.004_bib49","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2009.05.004_bib50","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.leu.2404554","article-title":"Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib","volume":"21","author":"Sherbenou","year":"2007","journal-title":"Leukemia"},{"issue":"42","key":"10.1016\/j.beha.2009.05.004_bib51","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1055\/s-2002-34939","volume":"127","author":"M\u00fcller","year":"2002","journal-title":"Dtsch Med Wochenschr"},{"issue":"s1","key":"10.1016\/j.beha.2009.05.004_bib52","first-page":"43","article-title":"Dynamics of mutant BCR-ABL positive clones after cessation of imatinib treatment","volume":"93","author":"Hanfstein","year":"2008","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.beha.2009.05.004_bib53","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/sj.leu.2404772","article-title":"BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?","volume":"21","author":"Legros","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2009.05.004_bib54","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2009.05.004_bib55","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2009.05.004_bib56","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2009.05.004_bib57","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2009.05.004_bib58","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.beha.2009.05.004_bib59","first-page":"625","article-title":"Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients","volume":"9","author":"Gambacorti-Passerini","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"5682","key":"10.1016\/j.beha.2009.05.004_bib60","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.beha.2009.05.004_bib61","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.beha.2009.05.004_bib62","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2009.05.004_bib63","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1073\/pnas.0409770102","article-title":"Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance","volume":"102","author":"Burgess","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.beha.2009.05.004_bib64","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/blood-2006-01-015347","article-title":"Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study","volume":"109","author":"Ray","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2009.05.004_bib65","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2009.05.004_bib66","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2009.05.004_bib67","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.beha.2009.05.004_bib68","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2009.05.004_bib69","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2009.05.004_bib70","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2009.05.004_bib71","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2009.05.004_bib72","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2009.05.004_bib73","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/sj.leu.2404509","article-title":"Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe\u2013impact of cost considerations","volume":"21","author":"Gratwohl","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.beha.2009.05.004_bib74","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","article-title":"Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia","volume":"109","author":"Hehlmann","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.004_bib75","doi-asserted-by":"crossref","first-page":"171a","DOI":"10.1182\/blood.V112.11.448.448","article-title":"Allogeneic hematopoietic stem cell transplantation (HSCT) in the imatinib-era: high survival rate following allogeneic HSCT after imatinib failure: results of the German CML Study IV","volume":"112","author":"Saussele","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2009.05.004_bib76","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.beha.2009.05.004_bib77","doi-asserted-by":"crossref","first-page":"129a","DOI":"10.1182\/blood.V112.11.333.333","article-title":"Molecular response to first line imatinib therapy is predictive for long term event free survival in patients with chronic phase chronic myelogeneous leukemia - An interim analysis of the randomized German CML Study IV","volume":"112","author":"M\u00fcller","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2009.05.004_bib78","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2007-06-096396","article-title":"In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib","volume":"111","author":"Khorashad","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2009.05.004_bib79","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.05.004_bib80","doi-asserted-by":"crossref","first-page":"403a","DOI":"10.1182\/blood.V112.11.1103.1103","article-title":"Homo-Harringtonine (Omacetaxine mepesuccinate) induces a dramatic and sustained reduction of BCR-ABLT315I mutated transcripts in chronic phase chromin myelogenous leukemia patients resistant to tyrosine kinase inhibitors","volume":"112","author":"Nicolini","year":"2008","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T00:59:13Z","timestamp":1590281953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692609000292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S1521692609000292"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2009.05.004","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}